Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery
The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.
Unlocking the Future of Life Sciences Research with AI, LLMs and Knowledge Graphs
In the world of life sciences, we’re standing at the edge of a transformative era. The last decade has seen machine learning carve out significant advancements, enabling experts to predict protein interactions and design molecules with unprecedented precision.
July 17, 2023
Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery
The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.
July 13, 2023
Identifying Targets in Gastrointestinal Stromal Tumors
Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.
July 12, 2023